Interferon beta-1b vs Rebif (interferon beta 1a)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline
Interferon beta-1b
Marketed by Bayer
NCT00099502 · Phase 3 · completed
The study was a large randomized, triple-blind, active-controlled trial comparing two interferon beta-1b doses with Copaxone, with relapse hazard as the clinical primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment); Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in Time (up to 60 months after start of treatment); Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60 (60 months after start of treatment): Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS (mixed)
Result source: NCT00185211
Rebif (interferon beta 1a)
Marketed by Merck KGaA and partners
NCT00110396 · Phase 3 · completed
The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.
Reported efficacy
Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Rebif New Formulation (RNF) Cohort 45 participants (not_applicable)
Result source: NCT00110396
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Interferon beta-1b | Rebif (interferon beta 1a) |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.3−0.1 vs placeboNCT00185211 | —Not posted · NCT00735007 |
| Free of 3-month confirmed disability progression (%) | —Not posted · NCT00099502 | —Not posted · NCT00735007 |
| New or enlarging T2 lesions | —Not posted · NCT00099502 | —Not posted · NCT00735007 |
Annualised relapse rate
- Interferon beta-1b
- 0.2 vs 0.3−0.1 vs placeboNCT00185211
- Rebif (interferon beta 1a)
- —Not posted · NCT00735007
Free of 3-month confirmed disability progression (%)
- Interferon beta-1b
- —Not posted · NCT00099502
- Rebif (interferon beta 1a)
- —Not posted · NCT00735007
New or enlarging T2 lesions
- Interferon beta-1b
- —Not posted · NCT00099502
- Rebif (interferon beta 1a)
- —Not posted · NCT00735007
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Interferon beta-1b: 4 of 4 rows · Rebif (interferon beta 1a): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Interferon beta-1b | Rebif (interferon beta 1a) |
|---|---|---|
| Dropout rate | 7.2%a NCT00185211 · Phase 3 · monotherapy show 1 more result5.1% NCT00370071 · Phase 3 · registry result, not featured evidence | 13.8%b NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more results—Non-Titrated NCT00472797 · Phase 3 · registry result, not featured evidence —Titrated NCT00472797 · Phase 3 · registry result, not featured evidence 13.8% NCT00428584 · Phase 3 · registry result, not featured evidence 24.5% NCT02727907 · Phase 2/3 · registry result, not featured evidence 4.4% NCT01071083 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%a NCT00185211 · Phase 3 · monotherapy show 1 more result— NCT00370071 · Phase 3 · registry result, not featured evidence | 5.8%b NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more results—Non-Titrated NCT00472797 · Phase 3 · registry result, not featured evidence —Titrated NCT00472797 · Phase 3 · registry result, not featured evidence — NCT00428584 · Phase 3 · registry result, not featured evidence — NCT02727907 · Phase 2/3 · registry result, not featured evidence 0% NCT01071083 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 20.9%a NCT00185211 · Phase 3 · monotherapy show 1 more result0% NCT00370071 · Phase 3 · registry result, not featured evidence | 5.8%b NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more results8.5%Non-Titrated NCT00472797 · Phase 3 · registry result, not featured evidence 5.3%Titrated NCT00472797 · Phase 3 · registry result, not featured evidence 6.2% NCT00428584 · Phase 3 · registry result, not featured evidence 0% NCT02727907 · Phase 2/3 · registry result, not featured evidence — NCT01071083 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a injection site reaction 55.8% (placebo 40.3%) flu syndrome 52.1% (placebo 51.1%) multiple sclerosis 38.4% (placebo 46.6%) NCT00185211 · Phase 3 · monotherapy show 1 more resultinfluenza like illness 41% hepathic function abnormal 17.9% headache 15.4% NCT00370071 · Phase 3 · registry result, not featured evidence | b influenza like illness 67.7% headache 37.7% injection site erythema 24.2% NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more resultsheadache 24.8% pain 14.2% influenza-like illness 8% NCT00472797 · Phase 3 · registry result, not featured evidence general disorders and administration site condition 67.7% infections and infestations 58.5% nervous system disorders 44.6% NCT00428584 · Phase 3 · registry result, not featured evidence flu-like syndrom 28.3% local reaction 28.3% neutropenia 20.8% NCT02727907 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 24.4% (placebo 11.9%) headache 17.8% (placebo 7.1%) dizziness 6.7% (placebo 0%) NCT01071083 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Interferon beta-1b
show 2 more results
show 2 more results
+ 9 further endpoints in the CSV export.
Rebif (interferon beta 1a)
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon beta-1b's landscape · Rebif (interferon beta 1a)'s landscape